Built for due diligence.
Every material claim we make, in one place — with primary sources linked. Verify us before you meet us.
Patent — filed and published.
The core method behind PulsEye — contactless vital-sign sensing via Wi-Fi Channel State Information — is the subject of a patent application filed in India in November 2025 and published in 2026.
- Covers the proprietary Wi-Fi CSI vital-sensing method at the heart of the platform.
- Noted in an ICMR MedTech Mitra Technical Advisory Committee forum — on the information presented — as a novel approach with no identified predicate device.
- Full filing details available to investors under NDA — request access.
The patented sensing platform.
TRL-6 — demonstrated, not theoretical.
The PulsEye prototype and MVP are complete, and the technology has been demonstrated in a relevant environment — the standard NASA/ISRO readiness definition of TRL-6.
TRL 7–9 — operational-environment demonstration through proven deployment — is the current execution focus.
See it, don't take our word.
PulsEye — product film I
PulsEye — product film II
Hardware, realised.
Industrial design renders of the completed PulsEye unit.
Testing photographs
Documentation of live signal-testing sessions will be published here.
Pilot case studies
Structured pilot results with partner facilities will be published here.
Won and shown, on the record.
Every achievement below links to its public source — the announcement, broadcast or gallery where it happened.
The signal keeps getting stronger.
From an identified problem to a product in the market — every bar of the signal, earned in sequence.
-
Phase 01
Problem Identified
Continuous monitoring fails the people who need it most: wearables get forgotten, cameras get rejected, and staff can't watch every room.
-
Phase 02
Problem Validated
Conversations with care facilities, families and clinicians confirmed the same unmet need, independently and repeatedly.
-
Phase 03
Foundational Research
Deep exploration of Wi-Fi CSI sensing established that heartbeat micro-motion could be recovered from ambient signal — reliably.
-
2023 · Phase 04
Incorporated
XZent Solutions Private Limited incorporated in Maharashtra; recognised under Startup India (DPIIT) as a deep-tech venture.
-
Phase 05
Advanced R&D
The signal-processing pipeline, AI models and purpose-built hardware matured from lab bench to working system.
-
2025 · Phase 06
Two National Hackathon Wins
Winner at IIT Bhubaneswar ReFlow 2025 and the Visakhapatnam Port Authority hackathon — validated by independent national juries.
-
Nov 2025 · Phase 07
Patent Filed
The core Wi-Fi CSI vital-sensing method filed in India in November 2025, published in 2026 — the platform's defensible moat.
-
2025 · Phase 08
Prototype Ready — TRL-6
Complete working prototype: custom hardware, edge processing and live heart-rate readout, demonstrated in a relevant environment.
-
Phase 09
MVP Ready
The prototype hardened into a deployable minimum viable product — installable, supportable and ready for real rooms.
-
Now · Phase 10
Entered Market
PulsEye is in the market. Full signal — and the roadmap ahead is where the platform compounds.
The roadmap, plainly stated.
Pilot Deployments
Structured pilots with care facilities, generating documented outcome data.
Clinical Validation
Formal validation studies benchmarking PulsEye readings against clinical reference devices.
Commercial Rollout
Scaled deployment across elderly care and assisted living, with platform capabilities expanding on the same hardware.
Noted by institutions that matter.
DPIIT-Recognised Startup
Registered under Startup India as a deep-tech venture — CIN U62099MH2023PTC409457.
ICMR MedTech Mitra
Discussed in a Technical Advisory Committee forum under ICMR's MedTech Mitra initiative; noted — on the information presented — as novel with no identified predicate device.
YourStory Feature (2026)
Spotlighted by YourStory, India's leading startup media platform. Read the feature →
Want the full data room?
Pitch deck, patent details and technical documentation are available to investors on request. We are currently engaging venture investors across India, the United States and Europe.